Celldex Therapeutics CLDX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's accounts payable?
- Celldex Therapeutics (CLDX) reported accounts payable of $10.36M in Q1 2026.
- How has Celldex Therapeutics's accounts payable changed year-over-year?
- Celldex Therapeutics's accounts payable increased by 203.8% year-over-year, from $3.41M to $10.36M.
- What is the long-term trend for Celldex Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), Celldex Therapeutics's accounts payable has grown at a 2.4% compound annual growth rate (CAGR), from $1.05M to $1.18M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.